The status and progress of tumor cell reduction combined with intraperitoneal hyperthermic perfusion chemotherapy (CRS/HIPEC) in the treatment of peritoneal metastasis of colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2020.02.004

Abstract

Abstract:

Peritoneum is the common site of colorectal cancer metastasis and always be regarded as the type with the poorest prognosis which relies on palliative treatment. Though chemotherapy and targeted drugs have made much progress on colorectal cancer, their effect on peritoneal metastasis are not quite well. Recently, more and more evidence indicates that the combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can achieve a long-term survival in selected patients with colorectal peritoneal metastasis. This review summarizes the current situation of CRS and HIPEC on different peritoneal metastasis and especially on colorectal peritoneal metastasis which indicates that the combination therapy modality is a safe and efficient way for colorectal peritoneal metastasis.

Key words: Colorectal neoplasms, Peritoneal metastasis, Cytoreduction surgery, Hyperthermic intraperitoneal chemotherapy

Lifeng Sun, Kefeng Ding. The status and progress of tumor cell reduction combined with intraperitoneal hyperthermic perfusion chemotherapy (CRS/HIPEC) in the treatment of peritoneal metastasis of colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2020, 09(02): 127-130.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2020.02.004

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2020/V09/I02/127

References 25

[1]	van Gestel YR, de Hingh IH, van Herk-Sukel MP, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer [J]. Cancer Epidemiol, 2014, 38(4): 448-454.
[2]	Kerscher AG, Chua TC, Gasser M, et al. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades [J]. Br J Cancer, 2013, 108(7): 1432-1439.
[3]	Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer [J]. Ann Oncol, 2016, 27(8): 1386-1422.
[4]	Brooks GA, Abrams TA, Meyerhardt JA, et al. Identification of potentially avoidable hospitalizations in patients with GI cancer [J]. J Clin Oncol, 2014, 32(6): 496-503.
[5]	Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer [J]. Ann Surg Oncol, 2008, 15(9): 2426-2432.
[6]	Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin [J]. J Clin Oncol, 2009, 27(5): 681-685.
[7]	Sugarbaker PH. Management of peritoneal metastases-Basic concepts [J]. J BUON, 2015, 20 (Suppl 1): S2-11.
[8]	Sugarbaker PH. Peritonectomy procedures [J]. Ann Surg, 1995, 221(1): 29-42.
[9]	Goere D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? [J]. Ann Surg, 2013, 257(6): 1065-1071.
[10]	Elias D, Matsuhisa T, Sideris L, et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance [J]. Ann Oncol, 2004, 15(10): 1558-1565.
[11]	Turaga K, Levine E, Barone R, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States [J]. Ann Surg Oncol, 2014, 21(5): 1501-1505.
[12]	Kuijpers AM, Mirck B, Aalbers AG, et al. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol [J]. Ann Surg Oncol, 2013, 20(13): 4224-4230.
[13]	Desolneux G, Maziere C, Vara J, et al. Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only [J]. PLoS One, 2015, 10(3): e0122816.
[14]	François QDE, Lise R, Diane G, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7 [J]. Journal of Clinical Oncology, 2018, 36: Lba3503-lba3503.
[15]	Esquivel J, Piso P, Verwaal V, et al. American society of peritoneal surface malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer [J]. J Surg Oncol, 2014, 110(7): 777-778.
[16]	O'Dwyer S, Verwaal VJ, Sugarbaker PH: Evolution of treatments for peritoneal metastases from colorectal cancer [J]. J Clin Oncol, 2015, 33(18): 2122-2123.
[17]	Benson AB, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: colon cancer, version 2.2018 [J]. J Natl Compr Canc Netw, 2018, 16(4): 359-369.
[18]	Goere D, Souadka A, Faron M, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study [J]. Ann Surg Oncol, 2015, 22(9): 2958-2964.
[19]	Simkens GA, van Oudheusden TR, Nieboer D, et al. Development of a prognostic nomogram for patients with peritoneally metastasized colorectal cancer treated with cytoreductive surgery and HIPEC [J]. Ann Surg Oncol, 2016, 23(13): 4214-4221.
[20]	Nishikawa T, Sunami E, Tanaka T, et al. Incidence and prognostic significance of positive peritoneal lavage in colorectal cancer [J]. Surg Today, 2015, 45(9): 1073-1081.
[21]	Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer [J]. Br J Surg, 2012, 99(5): 699-705.
[22]	Segelman J, Akre O, Gustafsson UO, et al. Individualized prediction of risk of metachronous peritoneal carcinomatosis from colorectal cancer [J]. Colorectal Dis, 2014, 16(5): 359-367.
[23]	Sammartino P, Sibio S, Biacchi D, et al. Prevention of peritoneal metastases from colon cancer in high-risk patients: preliminary results of surgery plus prophylactic HIPEC [J]. Gastroenterol Res Pract, 2012, 2012: 141585.
[24]	Klaver CE, Musters GD, Bemelman WA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial [J]. BMC Cancer, 2015, 15: 428.
[25]	Klaver CEL, Wisselink DD, Punt CJA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial [J]. Lancet Gastroenterol Hepatol, 2019, 4(10): 761-770.

Please choose a citation manager

Content to export